SillaJen Inc (215600 KQ) stock market data APIs
₩3667.7015
-281.86(-7.7%)
as of December 11, 2025
Try our APIs with
free plan!
SillaJen Inc Financial Data Overview
Price chart is built with
Anychart
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Prev. Close
3667.7015
Open
3385.8438
High
3823.5674
Low
3374.916
52 wk Range
1873-4700
Market Cap
511 080 M
Shares Outstanding
138 M
Revenue
7 841 M
EPS
-42.5454
Beta
0.044
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SillaJen Inc data using free add-ons & libraries
Get SillaJen Inc Fundamental Data
SillaJen Inc Fundamental data includes:
- Net Revenue: 7 841 M
- EBITDA: -24 217 206 784
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SillaJen Inc News
New
Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance
Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net salesSecond oncology transaction as part of strate...
Basilea gibt Verkauf der Rechte an Onkologie-Wirkstoff BAL0891 an SillaJen bekannt und aktualisiert Finanzausblick
Abschlags- und kurzfristige Meilensteinzahlungen von USD 14 Mio. Weitere Meilensteinzahlungen in Höhe von rund USD 320 Mio. und gestaffelte Lizenzgebühren auf NettoumsätzeZweite Onkologie-Transakti...
Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance
Basilea Pharmaceutica AG Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net sales Second oncology t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
